Howard A. “Skip” Burris, III, MD

Howard A. “Skip” Burris, III, MD, president, Clinical Operations, chief medical officer and executive director, Drug Development Program, Sarah Cannon, discusses the novel agents in breast cancer and monoclonal antibodies.